Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

Detalles Bibliográficos
Autores principales: Schentag, J, Opal, S, Lynn, M, Wittek, A, Wheeler, J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776178/
http://dx.doi.org/10.1186/cc8061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776178/
http://dx.doi.org/10.1186/cc8061

Ejemplares similares